Datroway
Datroway ingredients
| Active ingredient | Strength |
|---|---|
| Datopotamab Deruxtecan | 100 mg/5mL |
What Datroway is used for
The FDA lists the approved uses on the official label (below). In the EU, datopotamab deruxtecan is approved as Datroway for:
Breast cancer Datroway as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic hormone receptor (HR)-positive, HER2-negative breast cancer who have received endocrine therapy and at least one line of chemotherapy in the advanced setting.
EU wording from the European Medicines Agency; US approved uses can differ.
Key facts
- Brand
- Datroway
- Generic name
- Datopotamab deruxtecan
- Made by
- Daiichi Sankyo Inc.
- Forms
- Injection, Powder, Lyophilized, For Solution
- Given
- Intravenous
- FDA approval
- Biologic licence (BLA) BLA761394
- On the US market since
- 2025
Official information
- Datroway prescribing information (FDA label) on DailyMed
- MedlinePlus drug information (search for Datopotamab deruxtecan)
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Datroway?
Datroway (Datopotamab deruxtecan) is a cancer medicine made by Daiichi Sankyo Inc., approved by the US FDA.
What are the ingredients of Datroway?
Datroway contains Datopotamab Deruxtecan (100 mg/5mL).
Is Datroway approved in Europe?
The same active substance is approved in the EU as Datroway.
From the FDA National Drug Code directory (open.fda.gov, public domain) and the European Medicines Agency medicines list. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, USA